Clinical relevance of Helicobacter pylori virulence factors in Iranian patients with gastrointestinal diseases by Bagheri, Nader. et al.
lable at ScienceDirect
Microbial Pathogenesis 100 (2016) 154e162Contents lists avaiMicrobial Pathogenesis
journal homepage: www.elsevier .com/locate/micpathClinical relevance of Helicobacter pylori virulence factors in Iranian
patients with gastrointestinal diseases
Nader Bagheri a, d, Fatemeh Azadegan-Dehkordi a, Mahmoud Raﬁeian-Kopaei b,
Ghorbanali Rahimian c, Majid Asadi-Samani b, Hedaytollah Shirzad a, *
a Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
b Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
c Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
d Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Irana r t i c l e i n f o
Article history:
Received 13 October 2015
Received in revised form
21 September 2016
Accepted 21 September 2016
Available online 22 September 2016
Keywords:
Helicobacter pylori
Gastritis
Peptic ulcers
Gastric cancer
Virulence factors* Corresponding author. Cellular and Molecular R
University of Medical Sciences, Shahrekord, Iran. Tel
3833330709.
E-mail address: shirzad1951@yahoo.com (H. Shirz
http://dx.doi.org/10.1016/j.micpath.2016.09.016
0882-4010/© 2016 Elsevier Ltd. All rights reserved.a b s t r a c t
Helicobacter pylori (H. pylori) usually colonizes the gastric mucosa of more than 50% of the human
population, causing an infection that may appear in early childhood and can persist for life. H. pylori is
suggested as the main cause of peptic ulcer and chronic gastritis. It is also associated with gastric cancer.
Its severity and symptoms depend on environmental factors, host susceptibility and bacterial compo-
nents, which allow H. pylori to switch between commensalism and pathogenicity. H. pylori is genetically
highly variable, and the variability which affects H. pylori virulence factors might be useful in identifying
the strains with different degrees of pathogenicity. The geographic distribution of distinct H. pylori ge-
notypes is largely unknown and should be established. The prevalence of more pathogenic genotypes in
certain areas may have important epidemiological consequences. It also might be associated with the
severity of H. pylori related diseases in such regions. Given that Iran is located in the Middle East and
Asian populations have revealed high levels of gastric cancer, it is of clinical interest to clarify the po-
tential of H. pylori virulence markers in predicting the associated clinical outcomes. In this review, clinical
relevance of adhesion molecules and signiﬁcant virulence factors of H. pylori in Iranian patients with
gastrointestinal diseases are discussed in comparison to other countries.
© 2016 Elsevier Ltd. All rights reserved.Contents
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Helicobacter pylori (H. pylori) is a ﬂagellated, microaerophilic
gram-negative bacillus with spiral-shape that colonizes the gastric
mucosa, causing gastroduodenal diseases such as peptic ulcer,
chronic gastritis, atrophic gastritis as well as gastric cancer [1e3].
More than 50% of the world's population is infected with H. pylori,
andmost of colonized individuals develop chronic inﬂammation. In
the majority of infected patients, H. pylori colonization does not
cause any symptoms [4]. However, long duration of infection with
H. pylori increases the risk of developing site-speciﬁc diseases.
About 0.1% of the infected patients develop mucosa-associated
lymphoid tissue (MALT) lymphoma, 1e3% develop gastric adeno-
carcinoma and 10% develop peptic ulcer disease [5]. Indeed, the
clinical consequences of H. pylori infection are determined by
multiple factors, including environmental factors (such as smoking,
high salt intake, malnutrition, vitamin and antioxidants deﬁciency),
genetic predisposition of the host, especially regarding certain cy-
tokines, receptor gene polymorphisms such as IL-1b, IL-8, IL-10, IL-
17A and TNF-a and gene regulation [6e12]. In addition to envi-
ronmental and host factors, H. pylori strain-speciﬁc factors play a
role in different clinical expression, too [13,14]. H. pylori are
genetically highly diverse bacteria, mostly due to high mutational
rates, that include large insertions or deletions and chromosomal
rearrangements that affect housekeeping and virulence genes [15].
Within the H. pylori virulence factors, genetic variation may ac-
count for differences in the pathogenic properties of strains, and
thus may help explain the discrepancies between the number of
infected individuals and those that end up developing gastric car-
cinoma [13,16]. In this review, we tried to explain the contribution
of H. pylori virulence factors to different clinical expressions. We
will mainly focus on cagA, vacA, adhesins and outer membrane
proteins [17]. These are virulence factors that show different fre-
quency and genetic variation between strains and that have been
more extensively studied, thus gaining clinical interest as putative
markers in different clinical expressions.2. The vacuolating cytotoxin A (vacA)
The vacuolating cytotoxin A (vacA) gene, which is an important
virulence factor of H. pylori and is present in all strains, encodes an
87 kD protein. The initial studies on vacA detected two main
polymorphic regions including the signal sequence (s1 and s2) and
two types of mid region (m1 and m2). However, more recent
studies have identiﬁed an intermediate (i1 and i2) region which is
located between the s and m regions [18,19]. The mosaic combi-
nation of s and m region allelic types determines the production of
the cytotoxin and is associated with pathogenicity of the bacteria
[20]. VacA is considered as a H. pylori toxin with multiple cellular
effects in various host cell types. The toxin inserts into the cell
membrane and forms anion-conducting channels. This seems to be
important for the modulation of other VacA activities including the
ability to induce large acidic vacuoles, which was the ﬁrst epithelial
cell phenotype attributed to the toxin [21]. VacA toxin interferes
with autophagy pathways of gastric cells, causes gastric epithelial
erosions in mice, induces cell apoptosis and causes cell necrosis. It
also has immunomodulatory properties by inhibiting T and B-
lymphocyte proliferation and activation [22,23]. VacA with anunknown mechanism has an indirect effect on T cells, too. It can
induce dendritic cells tolerance and regulatory T cell induction;
however this effect has not been yet documented in human cells
[24,25]. It also induces a proinﬂammatory effect on T cells which is
mediated by activation of NF-kB and leads to upregulation of IL-8
[25].
The mosaic combination of the vacA s and m region alleles can
give rise to s1/m1, s1/m2, s2/m1 and s2/m2 type strains. There is
typically no vacuolating activity in s2/m2 strains, however, vacA s1/
m1 chimeric strains induce greater vacuolation than do s1/m2
strains [20,26,27]. The i region plays a functional role in vacuolating
activity, since vacA s1/i1/m2 strains are vacuolating types and vacA
s1/i2/m2 strains do not induce vacuolation. All vacA s1/m1 alleles
are of type i1, all s2/m2 alleles are of type i2, and s1/m2 alleles can
be either i1 or i2 [20].
Recently, a deletion of 81 bp between the i region and m region
was identiﬁed which was termed d region. D1 strains have no
deletion, however, the strains of the d2 type contain a 69- to 81-bp
deletion for a small number of Western strains, but not East Asian
strains [28].2.1. Clinical relevance of vacA genotypes in different clinical
expression
The ﬁrst studies evaluating the role of vacA genotypes in gastric
disease showed an association between the vacA s1 strains and
enhanced inﬂammation of the mucosa [29e31]. However, more
detailed analyses of gastritis parameters in the context of H. pylori
infection showed that vacA s1 and vacA m1 genotypes were asso-
ciated with higher levels of neutrophilic and lymphocytic in-
ﬁltrates, gastric atrophy, epithelial damage and intestinal
metaplasia [31]. Furthermore, studies including Brazilian, Portu-
guese, South African, Italian and German patients showed that
H. pylori vacA s1 and m1 strains were more frequently observed in
gastric carcinoma in comparison to chronic gastritis patients
[32e35]. In Western populations, the vacA s1/m1 allele is strongly
associated with duodenal and gastric ulcer disease as well as with
gastric cancer [32,36]. The evaluation of 135 chronic superﬁcial
gastritis and 130 gastric carcinoma patients from Portugal, showed
that patients infected with vacA s1 and m1 strains had respectively
17- and 6.7-fold increased risk for gastric carcinoma comparedwith
those infected with vacA s2 and m2 strains [33]. The study of
Kamali-Sarvestani and colleagues revealed a signiﬁcant difference
in vacA genotype distribution between gastric cancer and gastritis
or peptic ulcer patients.
The signiﬁcant increased level of s1m1 genotype in gastric
cancer patients in comparison with those in patients with peptic
ulcer or gastritis conﬁrms the pathogenic role of this virulence
determinant in Iranian patients [37]. Another study in Iranian pa-
tients demonstrated that the presence of m1 allele was associated
with duodenal and gastric ulcer, whereas all patients with gastritis
hadm2 allele [38]. It has been reported that association of allele m1
and histological alterations has related to an increase in epithelial
damage (microscopic erosions, epithelial degeneration and mucus
depletion) in contrast to reports on allele m2 [39].
Several studies in Iranian patients revealed that there was not
any association between vacA status and different clinical outcomes
including duodenal ulcer, gastric ulcer, gastritis, and non-ulcer
N. Bagheri et al. / Microbial Pathogenesis 100 (2016) 154e162156dyspepsia in Iranian patients [40e43] (Table 1). Study in Iranian
patients indicated that vacA i1, s1 and m1 strains were strongly
associated with gastric cancer [20,29]. This result was further
supported by Basso et al. [31] in an Italian population. Among
H. pylori strains isolated from patients in Iraq and Italy, vacA i1
strains were associated with gastric ulcer disease [29,31,44].
However, in East Asian and Southeast Asian populations, where the
incidence of gastric cancer is high, vacA i-region subtype is not
associated with risk of disease [45]. Other studies from Iran
revealed that s1 allele is associated with peptic ulcer disease
including duodenal ulcer and gastric ulcer and also s1 and s1m2
strain is dominant genotype among infected Iranian patients
[30,37,42,44,46e49]. Similarly, s1m2 genotype was shown to be
predominant in Turks and in Western countries [50]. However, the
vacA s1m1 genotype is more predominant in Afghani and Indian
strains [42,51,52]. Similar to other reports [30], Molaei et al. also
found that cagA and vacA s1 were highly associated with each other
and vacA s2 genotype was more frequent in cagA negative patients.
Moreover, patients with type s1 strains had more severe degree of
mononuclear cell inﬁltration in comparison to type s2 strains [53].
The vacA d-region remains poorly studied. The only study in
Western countries revealed that infection with vacA d1 strains
signiﬁcantly increased the risk for gastric carcinoma when
compared with infection with d2 strains, and was associated with
increased neutrophil inﬁltration and gastric atrophy, independent
of the vacA s-, m-, and i-region genotypes. In contrast, in East Asian
countries, there was no relationship between the vacA d-genotypes
and clinical outcome or histopathological changes in the gastric
mucosa [28].Table 1
Prevalence of vacA genotype of H. pylori in Iranian patients with gastrointestinal disease
Group [n] Allelic
variants
Disease group
Gastritis Peptic ulcer Non-
patie
Gastric ulcer Duodenal
ulcer
No. of
patients (%)
No. of
patients (%)
No. of
patients (%)
No. o
patie
shiraz
(Iran
1)
Gastritis ¼ 199
Gastric Ulcer ¼ 12
Duodenal
Ulcer ¼ 67
Gastric
Cancer ¼ 20
s1m1
s1m2
s2m1
s2m2
48 (26.5)
74 (40.9)
Not seen
59 (32.6)
21 (32.3)
33 (50.8)
Not seen
11 (16.9)
e
Guilan
(Iran
2)
Gastritis ¼ 29
Gastric Ulcer ¼ 13
Duodenal
Ulcer ¼ 35
s1
s2
m1
m2
16 (29)
0 (0)
29 (100)
10 (77)
8 (61)
29 (83)
23 (66)
e
Tehran
(Iran
3)
Gastritis ¼ 32
Gastric Ulcer ¼ 30
Duodenal
Ulcer ¼ 43
Non-Ulcer
Dyspepsia ¼ 35
s1
s2
m1
m2
s1m1
s1m2
s2m1
s2m2
19 (59.4)
13 (40.6)
7 (15.7)
25 (84.3)
5 (15.6)
12 (37.5)
5 (15.6)
10 (31.3)
22 (73.4)
8 (26.6)
12 (40)
18 (60)
5 (16.7)
15 (50)
2 (6.6)
8 (26.7)
35 (81.4)
8 (18.6)
20 (46.6)
23 (53.4)
11 (25.6)
22 (51.2)
4 (9.2)
6 (16)
21 (6
14 (4
47 (3
27 (7
8 (22
64 (4
14 (1
9 (25
Tehran
(Iran
4)
Gastric Ulcer ¼ 25
Duodenal
Ulcer ¼ 25
s1
s2
m1
m2
e 25 (100)
0 (0)
14 (56)
11 (44)
25 (100)
0 (0)
17 (68)
8 (32)
e
Tehran
(Iran
5)
Gastritis ¼ 12
Peptic Ulcer
Disease ¼ 8
Non-Ulcer
Dyspepsia ¼ 36
Gastric Cancer ¼ 5
s1
s2
m1
m2
s1m1
s1m2
s2m1
s2m2
9 (75)
3 (25)
4 (33.3)
8 (66.7)
3 (25)
5 (41.6)
0 (0)
4 (33.3)
8 (100)
0 (0)
2 (25)
6 (75)
2 (25)
6 (75)
0 (0)
0 (0)
25 (6
11 (3
11 (3
25 (6
12 (3
14 (3
0 (0)
10 (23. The cytotoxin associated gene A (cagA)
H. pylori strains are divided into twomain subpopulations based
on their capability to produce a 120e145-kDa immunodominant
protein called cytotoxin-associated gene A (CagA) antigen. The cagA
gene that encodes cagA is localized at one end of the cag PAI, a 40 kb
DNA segment that was most likely incorporated into the H. pylori
genome by a process of horizontal transfer state [56]. The cagA gene
is present in 44%e91% of H. pylori strains in Iranian patients
[37,40,48,57]. This result is different from the reports from South
and East Asianwhere the presence of cagA strain and its association
with clinical outcomes is more than 90% [46,58]. It has been shown
that the prevalence of cagA-positive strains in USA and Europe is
60e70% [59] which is more similar to our ﬁndings than in different
places of Asia. Prevalence of cagA in different geographical areas of
Iran is still under debate.
The cagPAI DNA segment possesses 31 putative genes, including
cagA and those encoding components of a molecular ‘syringe’
termed the type IV secretion system (T4SS), through which mac-
romolecules are delivered from the inside to the outside of the
bacterium [59]. The cagL gene, which is also located in the cagPAI,
encodes the CagL protein which is expressed on the surface of
H. pylori in a T4SS-dependent manner [60]. Upon the attachment of
cagA-positiveH. pylori to the gastric epithelial cell, the CagA protein
is injected directly into the cell [61]. Upon injection, unphos-
phorylated CagA interacts with host cell proteins. This causes
dysregulation of epithelial structure, integrity through its effect on
host cell signaling and induction of pro-inﬂammatory, as well as
mitogenic responses [62,63]. CagA is not only injected into gastrics.
Results References
ulcer
nts
Gastric
cancer
f
nts (%)
No. of
patients (%)
12 (66.7)
3 (16.7)
Not seen
3 (16.7)
Association with the type of disease [37]
e s1 and m1 allele was associated with duodenal
and gastric ulcer.
[38]
0)
0)
3.6)
7.1)
.8)
5.8)
0)
.7)
e No association with the type of disease [40]
e vacA allele s1 of this bacterium is associated
with ulcer
[54]
9.4)
0.6)
0.6)
9.4)
3.3)
8.8)
7.7)
4 (80)
1 (20)
1 (20)
4 (80)
1 (20)
3 (60)
0 (0)
1 (20)
No association with the type of disease [55]
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murine, as well as human dendritic cells (DCs) [64e66]. Remark-
ably, CagA translocation into DCs suppresses host immune
response by reducing the secretion of pro-inﬂammatory cytokines
as IL-12p40 and enhancing the expression of the suppressive
cytokine IL-10, indicating a dual pro- and anti-inﬂammatory role
for CagA during H. pylori infection dependent on the cellular
context [66,67]. The cagA gene contains a 50 end which is highly
conserved and a 30 end which is variable. The 3'-variable region
contains several repeat sequences, each of which contains an EPIYA
motif; the size variation in cagA correlates with the number of
repeat sequences located in this region. Once translocated into the
host cells, cagA is tyrosine phosphorylated on EPIYA motifs by ABL
and SRC family kinases [68,69]. The tyrosine phosphorylation site of
cagA is characterized by the presence of a unique Glu-Pro-Ile-Tyr-
Ala (EPIYA) motif, which is present in multiple numbers in the
carboxyterminal region of the protein [70]. From the sequences
ﬂanking these EPIYA motifs, four distinct EPIYA segments, EPIYA-A,
B, C and D, each of which contains a single EPIYA motif, have been
identiﬁed in the CagA protein [71]. EPIYA motifs in Western
H. pylori isolates such as those from Australia, North America and
Europe, are classiﬁed as EPIYA-A, EPIYA-B, and EPIYA-C and are
deﬁned by the amino acid sequences surrounding the EPIYAmotifs.
It has been suggested that the number of EPIYA-C sites directly
correlates with the level of tyrosine phosphorylation, SHP-2 bind-
ing activity, and cell damage. CagA proteins in East Asian H. pylori
isolates such as Japan, Korea and China possess EPIYA-A, EPIYA-B,
and EPIYA-D motifs; the EPIYA-D motif has a higher afﬁnity for
SHP-2 than does the Western EPIYA-C motif and appears to induce
morphological changes that involve cell-shapemodulation and that
result in cell elongation [72,73]. The tyrosine residue which con-
stitutes the EPIYA-C site seems to be the main site of tyrosine
phosphorylation in Western cagA by SFK in gastric epithelial cells.
However, those present in the EPIYA-A and EPIYA-B segments are
porly phosphorylated in the cells [59,70]. Furthermore, the exper-
iments on transgenic mice models also provided evidence that the
East Asian-type cagA is more carcinogenic than the Western-type
cagA [74].
3.1. Clinical relevance of cagA genotypes in different clinical
expression
The CagA protein has oncogenic potential. Infection with cagA-
positive strains is associated with higher degrees of epithelial
damage, chronic inﬂammation and neutrophilic activity in the
gastric mucosa, as well as increased risk of gastric atrophy and
intestinal metaplasia, compared to infection with cagA-negative
strains [33,75e77]. Both intensity of inﬂammation and epithelial
damage might be involved in the pathogenesis of peptic ulceration
[78]. In a study conducted in Spain, patients infected with cagA-
positive strains had 2.3-fold increased risk of progression of gastric
precancerous lesions in comparison with those infected with cagA-
negative strains [79]. In a meta-analysis study which included the
cross-sectional and case-control trials with cagA seroprevalence or
cagA detection by PCR, the odds ratios for gastric carcinoma in
cagA-positive infections were respectively 2.1 (95% CI, 1.5e2.9) and
2.4 (95% CI, 1.3e4.7), compared with normal controls, and with
gastritis controls, [80]. Several studies in Iranian patients demon-
strated that there were no associations between cagA and different
clinical outcomes including gastric cancer and gastritis or peptic
ulcer, which is in accordance with the results of other Asian
countries [37,40e42] (Table 2). A low prevalence of cagA has been
reported among MALT lymphoma and gastric cancer patients, and
there is no correlation between cagA gene and MALT lymphoma
and gastric cancer patients [81]. Several studies from the northernareas of Iran indicated that there was a stronger correlation be-
tween cagA gene and severe gastroduodenal complications such as
gastric cancer [82,83]. Salehi and Jafarzadeh reported that there
was a stronger correlation between cagA gene and duodenal ulcer
disease than with gastritis. In the gastric ulcer group, the preva-
lence of cagA positivity was 77% [38,78,84,85]. Study of Yadegar
et al. in Iranian patients indicated that there was a signiﬁcant
relationship between both cagL and cagA positivity and H. pylori
density in the antrum [55]. Only one study in Iranian patients
showed that the most frequent type of cagA 30 region was type A
(74%) and they did not ﬁnd the type C reported by Yamaoka et al.
[52], but they observed the subtypes of B or D (26%). Moreover their
study did not support the view that the subtypes of 30 region of
cagA gene in H. pylori isolated from Iran are correlated with the
clinical outcomes of H. pylori [78]. Unlike the previous studies,
Shokrzadeh et al. [86] revealed that there were no strains with
EPIYA-D segments, in agreement with the studies examining Ira-
nian strains [44,87,88]. The structure of the 30 region of the cagA
gene in Iranian strains was Western type. Furthermore, their study
did not support differences between EPIYA types and clinical
outcomes.
4. Adhesins and OMPs
Adherence of H. pylori to the gastric epithelium facilitates
persistence of infection, initial colonization and delivery of viru-
lence factors to host epithelial cells. The adherence of H. pylori to
the gastric mucosa is important for protection from mechanisms
such as mucus, acidic pH, and exfoliation [89,90]. H. pylori adhesins
which are considered as bacterial virulence factors are involved in
numerous processes during early and chronic phases of infection.
They also contribute to the differential outcome in infected patients
by triggering disease development. Approximately 4% of the
H. pylori genome is predicted to encode outer membrane proteins
[17], which is signiﬁcantly more than that for other known bacterial
species [91].
4.1. OipA
The outer inﬂammatory protein A (Oip A) is a 35 kDa pro-
inﬂammatory protein which is an inﬂammation related outer
membrane protein. The exact role of OipA is still not clear. OipA
expression is linked to increased IL-8 production in vitro [92].
Recent work using Mongolian gerbils infected with wild-type
H. pylori and an isogenic oipA mutant strain demonstrated a role
for oipA in induction of the mucosal cytokines IL-1, IL-17, and tumor
necrosis factor alpha (TNF-a) and in gastric mucosal inﬂammation
[93]. Also oipA is involved in upregulation of matrix metal-
loproteinase 1 (MMP-1) [94].
4.2. BabA
Blood group antigen binding adhesin (BabA) is a 75-kDa adhe-
sion molecule that mediates the attachment of H. pylori to Lewisb
blood group antigens on human gastric epithelial cell. Three bab
alleles namely babA1, babA2, and babB have been identiﬁed. BabA1
and babA2 are identical alleles except that babA1 has a 10-bp
deletion of the translational initiation codon. Only the babA2
gene product is necessary for Lewisb binding activity [95]. About
70% of H. pylori strains in Western countries were typed as babA2,
which was associated with increased virulence [96].
4.3. DupA
Recently, Lu et al. described a new putative H. pylori virulence
marker located in the “plasticity region” of the H. pylori genome.
The authors suggested the name dupA (duodenal ulcer-promoting
Table 2
Prevalence of cagA genotype of H. pylori in Iranian patients with gastrointestinal diseases.
Genotype Disease group Results References
All patients Gastritis Peptic ulcer Non-ulcer
patients
Gastric cancer
Gastric ulcer Duodenal ulcer
No. of patients
(%)
No. of patients
(%)
No. of patients
(%)
No. of patients
(%)
No. of patients
(%)
No. of patients
(%)
shiraz
(Iran 1)
cagA-Positive
cagA-
Negative
219 (76.5)
67 (23.5)
148 (74.4)
51 (25.6)
54 (80.6)
13 (19.4)
e 17 (85)
3 (15)
No association with the type of
disease
[37]
Iran 2
(Guilan)
cagA-Positive
cagA-
Negative
52 (67.5)
25 (32.5)
14 (48)
15 (52)
10 (77)
13 (33)
28 (80)
7 (20)
e e Association with peptic ulcer
disease
[38]
Guilan
(Iran 3)
cagA-Positive
cagA-
Negative
76 (71)
31 (32.5)
11 (46)
13 (54)
33 (77)
10 (33)
32 (80)
8 (20)
e e Association with duodenal ulcer [78]
Tehran
(Iran 4)
cagA-Positive
cagA-
Negative
98 (70)
42 (30)
18 (56.3)
14 (43.7)
21 (70)
9 (30)
35 (81.4)
8 (18.6)
24 (68.6)
11 (31.4)
e No association with the type of
disease
[40]
Tehran
(Iran 5)
cagA-Positive
cagA-
Negative
52 (85.2)
9 (14.8)
10 (83.3)
2 (16.6)
7 (87.5)
1 (12.5)
31 (86.1)
5 (13.9)
4 (80)
1 (20)
No association with the type of
disease
[55]
Tehran
(Iran 6)
cagA-Positive
cagA-
Negative
45 (76)
14 (24)
e 13 (76.4)
4 (23.6)
32 (76)
10 (24)
e No association with the type of
disease
[44]
Sari
(Iran 9)
cagA-Positive
cagA-
Negative
84 (65.6)
44 (34.4)
63 (85.1)
11 (14.9)
e e 16 (57.1)
12 (42.9)
No association with the type of
disease
[81]
Tehran
(Iran 7)
cagA-Positive
cagA-
Negative
EPIYA-AB
EPIYA-ABC
EPIYA-ABCC
92 (73.6)
49 (26.4)
3 (3.3)
86 (93.5)
3 (3.3)
e 0
10
1
3
73
1
0
3
1
No association with the type of
disease
[86]
Tehran
(Iran 8)
EPIYA-ABC
EPIYA-ABCC
EPIYA-
ABCCC
Mixed Types
Undeﬁned
Type
30 (68)
4 (9)
1 (2)
6 (14)
3 (7)
e EPIYA-ABCC association with
duodenitis
[88]
Iraqi
(Dohuk)
cagA-Positive
cagA-
Negative
35 (71)
14 (29)
e 19 (95)
1 (5)
16 (55)
14 (45)
e Association with peptic ulcer
disease
[44]
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duodenal ulcer and protection against gastric carcinoma, gastric
atrophy and intestinal metaplasia in Korea and Japan. An associa-
tion between dupA and increased expression levels of IL-8 has been
reported in the gastric mucosa of H. pylori-infected subjects
[97e99], but neither dupA1 nor dupA2 were found to induce IL-8
secretion by gastric epithelial cells. However, DupA1 was found to
increase pro-inﬂammatory cytokine expression, most markedly IL-
12p40, IL-12p70, and IL-23 by CD14þmononuclear cells, whichmay
explain how dupA1 contributes to gastric inﬂammation [98].
4.4. iceA1/2
A novel gene has recently been discovered, designated iceA
(induced by contact with epithelium). There are two main allelic
variants of the gene: iceA1 and iceA2. The expression of iceA1 is up-
regulated by contact between H. pylori and human epithelial cells
[17].
4.5. Clinical relevance of adhesins and OMPs in different clinical
expression
The prevalence of dupA is signiﬁcantly higher in strains of sub-
jects having duodenal ulcer but lower in patients with gastric
cancer (42% vs 9% on average), regardless of nationality (Japan,
Korea and Colombia) [100,101]. A review study reported that theprevalence of dupA in subjects with gastritis worldwide was 44.88%
and differed signiﬁcantly among nationalities and ethnicities [102].
The correlation between dupA status and disease development can
be found in several Asian countries. A meta-analysis study
including 17 trials with a total of 2466 patients was performed to
conﬁrm the association between the dupA and clinical outcomes,
and we revealed that the overall prevalence of the dupA gene was
31.0% (496/1600) in Asian countries and 64.1% (526/820) in West-
ern countries. Infection with dupA-positive H. pylori increased the
risk of duodenal ulcer (OR 1.41, 95% conﬁdence interval [CI]
1.12e1.76) in Asian countries (OR 1.57, 95% CI 1.19e2.06) but not in
Western countries (OR 1.09, 95% CI 0.73e1.62) [103]. However,
there was no association between the presence of dupA and gastric
cancer or gastric ulcer. Furthermore, studies have reported that the
presence of dupA was signiﬁcantly associated with eradication
failure [104]. Studies in Iranian patients revealed that possession of
dupA was inversely correlated with dysplasia such that 83.3% of
dysplasia-positive patients were colonized with dupA-negative
strains however; only 30.2% of dysplasia-negative patients were
colonized with dupA-positive. The presence of lymphoid follicles
was also inversely associatedwith dupA-positive strains, taking into
account that 81.3% of patients with no lymphoid follicles possessed
dupA-positive strains whereas only 52.1% of patients with lymphoid
follicles were infected with these strains. Also the presence of the
N. Bagheri et al. / Microbial Pathogenesis 100 (2016) 154e162 159dupA gene was not related to chronic gastritis, gastric ulcer,
duodenal ulcer, atrophy, intestinal metaplasia or the presence of
H. pylori [105] (Table 3). These ﬁndings are in accordance with the
results of Argent et al. [106], who demonstrated a lack of associa-
tion between the presence of dupA and duodenal ulcer in strains
isolated from four different geographical regions of the United
States, South Africa, Belgium and China. Furthermore, Gomes et al.
[107] also reported the lack of association of dupA with duodenal
ulcer as well as gastric cancer in both Brazilian adults and paedi-
atric patients. In contrast, Arachchi et al. [101] conﬁrmed the as-
sociation of dupAwith DU as an informative virulence marker. OipA
was more frequently detected in duodenal ulcer and gastric cancer,
but signiﬁcant effect on gastroduodenal diseases was not found.
Previous reports showed that oipA-positive status related with the
development of duodenal ulcer and gastric cancer [108,109]. A
recently published study in Iranian patients revealed that oipA-
positive patients had higher neutrophil activity and H. pylori den-
sity in gastric biopsy specimens [30]. OipA expression was reported
to be linked to severe inﬂammation and the presence of a func-
tional gene is signiﬁcantly associated with the presence of gastric
cancer, duodenal ulcer, and increased neutrophil inﬁltration
[108,110]. A study on Iranian patients demonstrated that the iceA1
allele was predominant [30,55]. This is in agreement with previous
reports from Turkey, Venezuela, Japan and Hong Kong, but different
from the strains in the Brazil and USA. Studies among South African
showed that iceA2 was predominant, however, iceA positivity was
not associated with any speciﬁc disease outcome [52,111,112].
Indeed, multiple iceA (iceA1þiceA2) genotypes which show mixed
infectionwith two or more different strains of H. pylori, were found
in Iranian patients of our isolates [30,55]. The prevalence of mixed
infections regarding multiple iceA genotypes was frequently re-
ported from other countries [113]. A meta-analysis including 50
studies with a total of 5357 patients was performed to conﬁrm the
relationship between the iceA allelic type and clinical outcomes,
and we revealed that the overall prevalence of iceA1 was signiﬁ-
cantly higher in Asian countries than in Western countries (64.6%
vs 42.1%), whereas iceA2 was more prevalent in Western countries
than in Asian countries (45.1% vs 25.8%). Sensitivity analysis inTable 3
Prevalence of other virulence factor of H. pylori in Iranian patients with gastrointestinal
Genotype Disease group
All patients Gastritis Peptic ulcer
Gastric ulcer Duodenal
ulcer
No. of
patients (%)
No. of patients (%) No. of
patients (%)
No. of
patients (%)
Tehran
(Iran 1)
dupA-Positive
dupA
-Negative
23 (39)
36 (61)
e 6 (35)
11 (65)
Tehran
(Iran 2)
dupA-Positive
dupA
-Negative
78 (49.7)
79 (50.3)
34 (50)
34 (50)
9 (39.1)
14 (60.9)
15 (50)
15 (50)
Iraqi
(Dohuk)
dupA
-Positive
dupA
-Negative
16 (32.7)
33 (67.3)
e 11 (55)
9 (45)
Tehran
(Iran 3)
babA2
-Positive
babA2-
Negative
59 (96.7)
2 (3.3)
12 (100)
0 (0)
8 (100)
0 (0)
Tehran
(Iran 5)
iceA1-Positive
iceA2-
Positive
iceA1/iceA2
mixed
26 (42.6)
14 (23)
21 (34.4)
7 (58.3) 3 (25) 2
(16.6)
3 (37.5)
3 (37.5)
2 (25)Western countries showed that the presence of iceA1 was signiﬁ-
cantly associated with peptic ulcer (OR 1.25, 95% CI 1.08e1.44). On
the other hand, the presence of iceA2 was inversely correlated with
peptic ulcer (OR 0.76, 95% CI 0.65e0.89) [113]. The binding speci-
ﬁcities of H. pylori strains worldwide suggest that the BabA adhesin
has evolved in response to host mucosal glycosylation patterns to
permit H. pylori to adapt to its host and to maintain persistent
colonization [114]. The presence of babA2 is associated with
duodenal ulcer disease and gastric cancer, and when found in
conjunction with cagA and vacA s1 alleles, it is associated with an
even greater risk of developing more severe disease [96]. More
recent analyses of babA2 as a virulence marker have shown con-
ﬂicting data on the usefulness of babA2 expression in predicting
clinical outcome, which is most likely dependent on the geographic
origin of the H. pylori strains. In Thai and Portuguese populations,
babA2 has not shown to be a biomarker for peptic ulcer disease or
gastric cancer [58,115]. However, for strains isolated from northern
Portugal, Turkey, and Germany babA2 expression is associated with
the severity of gastric disease [96,116,117].
5. Conclusion
H. pylori plays a central role in the pathogenesis gastrointestinal
disorder. The complex combination of environmental, host, and
bacterial factors determines the susceptibility and severity of
outcome ofH. pylori infection and related pathology in the subset of
individuals. Iran is located in the Middle East between Europe and
East Asian countries, and has close economic and cultural re-
lationships with both regions. Although in Iran, the patterns of the
prevalence of vacA genotypes is similar to those in European
countries [20,37,47,118], it is unclear whether cagA EPIYA sequences
in Iranian strains are similar to the Western type or not. The
number and/or kind of EPIYA motifs/segments in Iranian strains
was not associated with gastro-duodenal diseases, due to few
previous information about the patterns of EPIYA motifs in the
Iranian population [44,78]. Besides, the presence of the dupA gene
in Iranian patients was not similar to Asian countries, and has no
association with gastro-duodenal diseases. But Western countriesdiseases.
Results References
Non-ulcer patients Gastric cancer
No. of patients (%) No. of patients
(%)
17 (40)
25 (60)
e No association with the type of
disease
[44]
e 20 (55.6)
16 (44.4)
No association with the type of
disease
5 (17)
24 (83)
e Association with peptic ulcer
disease
[44]
34 (94.4)
2 (5.5)
5 (100)
0 (0)
No association with the type of
disease
[55]
13 (36.1) 7 (19.4) 16
(44.4)
3 (60) 1 (20) 1
20)
No association with the type of
disease
[55]
N. Bagheri et al. / Microbial Pathogenesis 100 (2016) 154e162160have similar results in this virulence factor. A better understanding
of the molecular mechanism for H. pylori-related inﬂammation and
gastric carcinogenesis would allow the identiﬁcation of more
effective therapeutic targets for gastric cancer. Further research
into Iranian host and H. pylori genetics would be warranted to draw
more far-reaching conclusions.
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